Hare
HomeInsights

INDUSTRY:

Pharma

TOPIC:

Regulatory & Legal

TITLE:

EMA: On the 18 September 2017, the European Commission granted a Marketing Authorisation for Xermelo (telotristat ethyl), indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The Marketing Authorization Holder for this medicinal product is Ipsen Pharma.

BRIEF:

EMA: On the 18 September 2017, the European Commission granted a Marketing Authorisation for Xermelo (telotristat ethyl), indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The Marketing Authorization Holder for this medicinal product is Ipsen Pharma.

LEGAL IMPLICATIONS:

BUSINESS IMPLICATIONS:

Special Report

In an unexpected move, just before the end of 2011, ...

Case Study

Improving expenditure efficiency has been, for a ver...

Your Portal Link to Mass Media Universe.

Valuable Quarterly Romanian Market Analysis.

Ask the analyst

Tailor-made advice for you

Feature Company